lipa

(redirected from Lysosomal Acid Lipase)
Also found in: Medical, Financial, Acronyms.

li·pa

 (lē′pə)
n. pl. lipa
A Croatian unit of currency equal to 1/100 of the kuna.

[Serbo-Croatian.]

lipa

(ˈliːpə)
n, pl lipa
(Currencies) a monetary unit of Croatia worth one hundredth of a kuna

li•pa

(ˈli pə)
n., pl. -pa.
a monetary unit of Croatia.
References in periodicals archive ?
Effect of Sebelipase Alfa on Survival and Liver Function in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency--Thursday, February 12 at 3:45 p.
Synageva) reported that its global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial for sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency (LAL Deficiency) earned positive top-line results by reaching primary endpoint of normalization of alanine aminotransferase (ALT), a marker of liver injury.
SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme.
NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that data from its Phase 3, global, double-blind, placebo-controlled trial evaluating sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency) were presented for the first time at a medical conference during the late-breaking session of The Liver Meeting, the 65[sup.
Natural history study of early onset Lysosomal Acid Lipase (LAL) Deficiency (Wolman disease) confirms a severe and rapid disease course," Christian Hendriksz, 1:00 pm-2:30 pm GMT
The company's pipeline programs consist of protein therapeutics for rare diseases with unmet medical need at various stages of development including the lead program, Kanuma(TM) (sebelipase alfa) for lysosomal acid lipase deficiency (LAL Deficiency), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome), and SBC-105 for generalized arterial calcification of infancy (GACI) and other rare calcification diseases.
SBC-102 is a recombinant form of the human LAL enzyme being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD).

Full browser ?